Berkan Kurt, MD

🫀 Now out in the #EHJ: “More than a sidekick: GIP signalling and cardiovascular outcomes” on (tw)incretins, inflammation and CVD.

#GIP mediated BMI lowering is linked to greater reductions in MACE/HF - possibly via anti-inflammatory effects.

Full text: academic.oup.com/eurheartj/ad...

23.12.2025 20:53 — 👍 2    🔁 0    💬 1    📌 0

Our article “C-reactive protein and cardiovascular risk in the general population” is now published in the European Heart Journal.

Open Access: academic.oup.com/eurheartj/ad...

@escardio.bsky.social @dgk-org.bsky.social

11.12.2025 17:40 — 👍 2    🔁 1    💬 0    📌 0

Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates - Current Heart Failure Reports Purpose of Review Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. Increasing evidence highlights that systemic low-grade inflammation is a key pathophysiological drive...

🫀 Out now: In our new review, we look at heart failure with a focus on chronic low-grade inflammation, discuss how hsCRP, IL-6 and other biomarkers capture residual inflammatory risk in HFpEF and HFrEF and may help guide future anti-inflammatory strategies. 🔥 💉

link.springer.com/article/10.1...

08.11.2025 13:28 — 👍 1    🔁 0    💬 0    📌 0

Adjustment of the SMART risk score by bioactive adrenomedullin enables a more accurate prediction of mortality in patients with ASCVD Bioactive adrenomedullin 1-52 (bio-ADM) is a novel biomarker for the assessment of endothelial function and prediction of adverse outcomes in patients with acute heart failure and cardiogenic shock. T...

Excited to share our new paper is now out in #Atherosclerosis:
In patients with #ASCVD, adding #bioADM to the ESC-recommended #SMART risk score improves risk prediction and model performance.

Thanks to all collaborators for the joint effort.

Read here (open access): tinyurl.com/3jtdhpzv

30.05.2025 08:50 — 👍 3    🔁 1    💬 0    📌 0